Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Loren Walensky
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aileron Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
See attached.
Dissecting and targetting HDMX-medicated chemoresistance in human cancer
PROJECT NARRATIVE Suppression of p53 by its negative regulator proteins HDM2 and HDMX underlies the chemoresistance of a host of human cancers. We find that a subset of resistant cancers is uniquely dependent on HDMX for survival but no selective inhibitors are currently available for treatment. I propose to apply multidisciplinary approaches to uncover the blueprint for selective HDMX targeting, determine the distinguishing structure-function mechanisms of the p53/HDM2/HDMX protein interaction network, and validate a new therapeutic strategy for reactivating p53-mediated cell death in chemoresistant cancers driven by HDMX expression.
Filed on August 01, 2017.
Tell us what you know about Loren Walensky's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Loren Walensky”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Loren Walensky | Harvard Medical School | Conflict of Interest | Aileron Therapeutics | Value cannot be readily determined |
| Loren Walensky | Dana Farber Cancer Inst | Conflict of Interest | Aileron Therapeutics | Value cannot be readily determined |
| Loren Walensky | Harvard Medical School | Conflict of Interest | Aileron Therapeutics | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.